Myöhänen, T T <br/><br/>
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.  [electronic resource] 

 -  British journal of pharmacology  Jun 2012 
 - 1097-113 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5381 
<br/><br/><label>Standard No.: </label>10.1111/j.1476-5381.2012.01846.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Blotting, Western<br/>Brain--drug effects<br/>Cell Culture Techniques<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Humans<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Transgenic<br/>Microscopy, Fluorescence<br/>Motor Activity--drug effects<br/>Oxidative Stress--drug effects<br/>Parkinsonian Disorders--drug therapy<br/>Proline--analogs & derivatives<br/>Prolyl Oligopeptidases<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Serine Endopeptidases--metabolism<br/>Serine Proteinase Inhibitors--pharmacology<br/>Transfection<br/>alpha-Synuclein--genetics